Project Lead(s): Cynthia Koenig
With new funding from Grand Challenges Canada and partners, Biosense aims to screen 3 million people and treat 1.5 million people for anemia.
Their affordable, portable and needle-free screening tool, TouchHb, reduces the need for timeconsuming lab analysis by pulling instant, reliable results from a non-invasive scan of a patient’s eyelid.
In trials, the device was shown to be more accurate than the current standard for anemia screening and more sensitive than any other non-invasive anemia screening device on the market.
The TouchHb device, fitted over a patient’s eye, can measure the patient’s blood haemoglobin levels using light, minimizing risk of contamination while providing rapid results without costly transportation and lab analysis. Biosense is seeking regulatory approvals to bring TouchHb to a broader market.
Some 1.5 billion people experience iron deficiency anemia every year, which is especially dangerous for pregnant women who may suffer from fatal blood loss during childbirth and give birth to a low birth weight baby. Babies born to anemic mothers are also more likely to experience developmental delays or suffer from anemia themselves.
Early detection can help reduce anemia-related deaths, but invasive tests that require needles, transportation materials, and extensive lab analysis are often out of reach for people living in low-resource settings. Tests like TouchHb are key to increasing anemia detection and preventing death for the hardest to reach populations.
Scaling Partners: Grand Challenges Canada; Strategic Partners; Government of Rajasthan; Villgro India; Eris Lifesciences Pharmaceuticals; the Government of India’s Department of Biotechnology; The Biotechnology Industry Research Assistance Council; GSF; Insitor Fund.